Maria Bensi

Maria Bensi

Auto-generated profile, based on publicly available information

Maria Bensi

Comprehensive Cancer Center, Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
MSMarta Schirripa
Marta Schirripa
FNFloriana Nappo
Floriana Nappo
CCChiara Cremolini
Chiara Cremolini
LSLisa Salvatore
Lisa Salvatore
DRDaniele Rossini
Daniele Rossini
FLFotios Loupakis
Fotios Loupakis

1 September 2020 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
DRDaniele Rossini
Daniele Rossini
MGMarco Maria Germani
Marco Maria Germani
FPFilippo Pagani
Filippo Pagani
APAntonio Pellino
Antonio Pellino
EDEmanuela Dell’aQuila
Emanuela Dell’aQuila
Chiara CremoliniChiara Cremolini
Chiara Cremolini

6 April 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CACarlotta Antoniotti
Carlotta Antoniotti
Alessandra BoccaccinoAlessandra Boccaccino
Alessandra Boccaccino
RSRobert Seitz
Robert Seitz
MGMirella Giordano
Mirella Giordano
ACAurélie Catteau
Aurélie Catteau
Chiara CremoliniChiara Cremolini
Chiara Cremolini
Purpose: AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), with a modest benefit among proficient mismatch repair (pMMR). DetermaIO is an immune-related 27-gene expression signature able to predict benefit from immune checkpoint inhibition in triple-negative breast cancer. In this analysis of AtezoTRIBE, we investigated the predictive impact of DetermaIO in mCRC. Experimental Design: Patients with mCRC unselected for MMR status were randomly assigned (1:2) to FOLFOXIRI plus bevacizumab (control arm) or the same regimen with atezolizumab (atezolizumab arm). qRT-PCR by DetermaIO was performed on RNA purified from pretreatment tumors of 132 (61%) of 218 enrolled patients. A binary result (IOpos vs. IOneg) adopting the preestablished DetermaIO cut-off point (0.09) was obtained, and an exploratory optimized cut-off point (IOOPT) was computed in the overall population and in pMMR subgroup (IOOPTpos vs. IOOPTneg). Results: DetermaIO was successfully determined in 122 (92%) cases, and 23 (27%) tumors were IOpos. IOpos tumors achieved higher PFS benefit from atezolizumab arm than IOneg (HR: 0.39 vs. 0.83; Pinteraction = 0.066). In pMMR tumors (N = 110), a similar trend was observed (HR: 0.47 vs. 0.93; Pinteraction = 0.139). In the overall population, with the computed IOOPT cut-off point (0.277), 16 (13%) tumors were IOOPTpos and they derived higher PFS benefit from atezolizumab than IOOPTneg (HR: 0.10 vs. 0.85, Pinteraction = 0.004). Similar results were found in the pMMR subgroup. Conclusions: DetermaIO may be useful to predict benefit of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in mCRC. The exploratory IOOPT cut-off point should be validated in independent mCRC cohorts.

12 April 2024 in ESMO Open
Verified
Journal Article
Open access
MGM.M. Germani
M.M. Germani
GVGuglielmo Vetere
Guglielmo Vetere
FSFiorenza Santamaria
Fiorenza Santamaria
RIR. Intini
R. Intini
FGF. Ghelardi
F. Ghelardi
Chiara CremoliniChiara Cremolini
Chiara Cremolini
Targeted therapy (TT) with encorafenib and cetuximab is the current standard for patients with BRAFV600E-mutated metastatic colorectal cancer (mCRC) who received one or more prior systemic treatments. However, the median progression-free survival (mPFS) is ∼4 months, and little is known about the possibility of administering subsequent therapies, their efficacy, and clinicopathological determinants of outcome. A real-world dataset including patients with BRAFV600E-mutated mCRC treated with TT at 21 Italian centers was retrospectively interrogated. We assessed treatments after progression, attrition rates, and outcomes. Of the 179 patients included, 85 (47%), 32 (18%), and 7 (4%) received one, two, or three lines of treatment after TT, respectively. Those receiving TT in the second line were more likely to receive at least one subsequent therapy (53%), as compared with those treated with TT in the third line or beyond (30%; P < 0.0001), and achieved longer postprogression survival (PPS), also in a multivariate model (P = 0.0001). Among 62 patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors receiving one or more lines of treatment after second-line TT, combinatory chemotherapy ± anti-vascular endothelial growth factor (anti-VEGF) was associated with longer PFS and PPS as compared with trifluridine-tipiracil or regorafenib (mPFS: 2.6 versus 2.0 months, P = 0.07; PPS: 6.5 versus 4.4 months, P = 0.04). Our real-world data suggest that TT should be initiated as soon as possible after the failure of first-line treatment in BRAFV600E-mutated mCRC. Among patients with pMMR/MSS tumors, combinatory chemotherapy ± anti-VEGF appears the preferred treatment choice after TT failure.

1 December 2021 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
MCMaria Alessandra Calegari
Maria Alessandra Calegari
BSBrunella Di Stefano
Brunella Di Stefano
MBMichele Basso
Michele Basso
CCCarmine Carbone
Carmine Carbone
FCFloriana Camarda
Floriana Camarda
GTGiampaolo Tortora
Giampaolo Tortora

16 September 2024
Verified
Other
Open access
CACarlotta Antoniotti
Carlotta Antoniotti
Alessandra BoccaccinoAlessandra Boccaccino
Alessandra Boccaccino
RSRobert Seitz
Robert Seitz
MGMirella Giordano
Mirella Giordano
ACAurélie Catteau
Aurélie Catteau
Chiara CremoliniChiara Cremolini
Chiara Cremolini
Baseline characteristics of patients according to the predefined and optimized DetermaIO score positivity cut-point in the pMMR tumours group.